Efficacy of lutein supplement on macular pigments density and visual performance of age-related macular degeneration (AMD) patients
Not Applicable
- Conditions
- age-related macular degeneration (AMD) patients
- Registration Number
- JPRN-UMIN000000635
- Lead Sponsor
- Raman Study Team
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 80
Inclusion Criteria
Not provided
Exclusion Criteria
(1) Eyes with cataract that affect the measurement of visual function tests. (2) Eyes received cataract surgery within six months (3) Eyes with glaucoma, diabetic retinopathy and any other eye disease (4) Patient with serious disease in liver, kidney or heart that impacts on the evaluation of the use of lutein supplements (5) Patient who is taking photosensitive medicine, such as phenothiazine, chloroquine or tetracycline (6) Patient who involved in the other clinical trials within three months (7) Others. Patients whom the principal investigator judges incompetent
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Measurements of visual acuity, contrast sensitivity, metamorphopsia graded by M-chart, perimetric mean sensitivity, and macular pigment density
- Secondary Outcome Measures
Name Time Method